Enanta Pharmaceuticals Inc (ENTA) Receives Average Rating of “Hold” from Brokerages

Shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) have received a consensus recommendation of “Hold” from the eleven ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $102.60.

ENTA has been the topic of several analyst reports. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, November 19th. BidaskClub raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, November 20th. Oppenheimer set a $100.00 target price on shares of Enanta Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, November 27th. Finally, Berenberg Bank initiated coverage on shares of Enanta Pharmaceuticals in a research report on Thursday, December 13th. They issued a “hold” rating and a $80.00 target price on the stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. State of Alaska Department of Revenue grew its position in Enanta Pharmaceuticals by 3.9% during the fourth quarter. State of Alaska Department of Revenue now owns 5,282 shares of the biotechnology company’s stock valued at $374,000 after purchasing an additional 200 shares in the last quarter. United Services Automobile Association grew its position in Enanta Pharmaceuticals by 1.7% during the second quarter. United Services Automobile Association now owns 37,289 shares of the biotechnology company’s stock valued at $4,322,000 after purchasing an additional 635 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in Enanta Pharmaceuticals by 22.6% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 3,747 shares of the biotechnology company’s stock valued at $320,000 after purchasing an additional 690 shares in the last quarter. Strs Ohio grew its position in Enanta Pharmaceuticals by 7.4% during the third quarter. Strs Ohio now owns 11,600 shares of the biotechnology company’s stock valued at $991,000 after purchasing an additional 800 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its position in Enanta Pharmaceuticals by 9.4% during the third quarter. Thrivent Financial for Lutherans now owns 10,849 shares of the biotechnology company’s stock valued at $927,000 after purchasing an additional 936 shares in the last quarter. 84.83% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals stock opened at $75.06 on Friday. The company has a market capitalization of $1.44 billion, a PE ratio of 21.57 and a beta of 0.99. Enanta Pharmaceuticals has a fifty-two week low of $57.52 and a fifty-two week high of $127.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, November 26th. The biotechnology company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.06. The business had revenue of $67.20 million for the quarter, compared to the consensus estimate of $69.03 million. Enanta Pharmaceuticals had a net margin of 34.82% and a return on equity of 21.56%. The firm’s quarterly revenue was down 11.5% compared to the same quarter last year. During the same period last year, the firm posted $1.86 earnings per share. As a group, research analysts predict that Enanta Pharmaceuticals will post 1.7 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

See Also: Net Income

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply